Determinants of Post-Treatment Phenotypes in Lyme Disease
莱姆病治疗后表型的决定因素
基本信息
- 批准号:10738012
- 负责人:
- 金额:$ 63.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAftercareAntibiotic TherapyAnxietyAutoantibodiesAutoantigensAutoimmune ProcessBiologyBlood PressureBorrelia burgdorferiCellular Metabolic ProcessClinicalCoculture TechniquesComplexDataDevelopmentDiseaseDisease PathwayEnvironmentEnzyme-Linked Immunosorbent AssayEtiologyEventFDA approvedFlow CytometryFunctional disorderFutureGoalsGrantHealthHumanImmuneImmunologicsImmunologyImmunoprecipitationIn VitroIndividualInfectionInterventionKnowledgeLaboratoriesLongitudinal StudiesLyme DiseaseMental DepressionMetabolicMetabolic PathwayMethodsModelingModernizationMolecularMusculoskeletal PainNeurologic SymptomsOutcomeParticipantPathogenesisPathway interactionsPatientsPeripheral Blood Mononuclear CellPersonsPhenotypePhysiologic pulseProcessProspective, cohort studyProtein ArrayProtein MicrochipsPsychosocial FactorPublishingQuality of lifeRecording of previous eventsReportingResearchRiskRisk AssessmentRisk FactorsSamplingSampling StudiesScientific Advances and AccomplishmentsSeriesSerologySerumSigns and SymptomsSortingStandardizationStressful EventSubgroupSymptomsSyndromeTestingTherapeuticTimeTranslationsTreatment outcomeUnited StatesUniversitiesVector-transmitted infectious diseaseWorkacute infectionbiobankcandidate identificationclinical careclinical phenotypeclinical practiceclinically relevantcohortcytokinehigh dimensionalityinnovationinsightmachine learning algorithmnovelpain symptomparticipant enrollmentpatient populationpatient subsetspharmacologicpreventpreventive interventionprofiles in patientsrecruitsextherapeutic targettranscriptome sequencingtranslational research program
项目摘要
PROJECT SUMMARY/ABSTRACT
It is unknown why some patients regain their pre-morbid health following appropriate treatment for Lyme disease
while others progress to develop post-treatment Lyme disease (PTLD). Significant prior published and
preliminary data suggest that variability in clinical, immunologic, and metabolic factors at the onset of infection
with B. burgdorferi contribute to the development of divergent post-treatment outcomes, including PTLD. In this
study, we will draw upon unique cohorts of patients with well-defined PTLD, healthy controls without a history of
Lyme disease, and patients with early Lyme disease followed longitudinally up to 1 year after the end of
treatment. Combining advanced, innovative statistical and laboratory methods, the objective of this grant is to
identify these factors and examine how they relate to underlying symptom phenotypes among patients with
PTLD. To accomplish this goal, we will identify clinically-relevant risk factors associated with post-treatment
outcomes in Lyme disease over time. These factors will then be used to develop an assessment score to identify
patients at increased risk of developing PTLD in the clinical setting (AIM 1). A longitudinal, multivariate, cross-
domain analysis of this sort with the goal of direct translation of findings to clinical practice and the study of
fundamental disease pathways in PTLD has not previously been performed. We will also identify novel auto-
antibodies that are associated with PTLD through protein array, and examine their relationship with underlying
clinical phenotypes (AIM 2). While an autoimmune process has been suspected to underlie the pathogenesis of
PTLD, at least for some individuals, adaptive immune recognition of self-antigens is only beginning to be
described. Discovery of autoantibodies in PTLD may reveal patient subsets marked by specific clinical features,
such as predominant musculoskeletal pain or neurologic symptoms, and identify individuals whose disease is
driven by an autoimmune process. Finally, we will study the longitudinal immunometabolic profile of patients with
differing clinical outcomes using a novel, high-dimensional flow cytometry approach, and hypothesize that
pharmacologic manipulation of perturbed pathways in vitro may be able to normalize a PTLD-associated
metabolic signature (AIM 3). The ability of immunometabolism to globally report on the acute cellular
environment suggests that interrogating immune cell metabolism in individuals develop PTLD in the future could
provide fundamental insights into disease mechanism. Collectively, our studies represent a rigorous approach
towards uncovering determinants that are associated with the outcome of PTLD and its underlying clinical
phenotypes. The long-term goal of this project is to generate fundamental knowledge to inform the development
of innovative therapeutic strategies as well as novel interventions to prevent or reduce the often significant
symptom burden and functional impact of PTLD.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Aucott其他文献
John Aucott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 63.51万 - 项目类别:
Research Grant














{{item.name}}会员




